Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study

Citations Over Time

Abstract

Abstract Background Patients with psoriasis often suffer from obesity. However, only limited data are available on the efficacy of brodalumab 210 mg, a fully human monoclonal immunoglobulin IgG2 antibody binding to the human interleukin 17 receptor subunit A, in obese patients in daily practice, to date. Objectives A subgroup analysis from the LIBERO study was conducted to compare the effectiveness of brodalumab in patients weighing ≤100 and >100 kg after ~12 weeks (W) and ~52 W. Methods LIBERO is a large prospective, multicenter, non‐interventional, real‐world‐evidence study including adult patients with plaque psoriasis treated with brodalumab 210 mg. Results Four hundred and sixty‐one patients with a body weight up to 100 kg (nonobese) and 161 patients with >100 kg body weight (obese) were included in this subgroup analysis. At baseline, the majority of patients in both groups had very severe (12.6%; 15.7%) or severe (49.4%; 55.0%) psoriasis, as assessed by Physician Global Assessment (PGA). As of W2, a significant reduction of the mean PASI could be achieved in both groups. In patients weighing ≤100 kg mean PASI decreased from 16.9 to 9.0 and further improved to 2.6 at ~W12 ( p < 0.001). In the patient group >100 kg, the PASI decreased from 17.9 to 10.2 at ~W2 ( p < 0.001) and improved further to 3.9 at ~W12 ( p < 0.001). However, at ~W12 absolute PASI0‐3 rates were lower in patients >100 kg than in patients ≤100 kg (68.4% vs. 80.5%, p = 0.006); there was no statistically significant difference between the groups at ~W52/last visit any more in any of the effectiveness parameters with, for example, a PGA0/1 response of 82.3% versus 86.5% ( p = 0.6089), respectively. Conclusions This subgroup analysis of LIBERO confirmed, that in daily practice brodalumab can be equally beneficial patients with >100 and ≤100 kg in the long‐term management of psoriasis.

Related Papers

• → Evaluation of 308‐nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis(2008)31 cited
• → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2016)14 cited
• → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2017)1 cited
• W jaki sposób miarodajnie oceniać nasilenie łuszczycy(2016)